LivaNova 향후 성장
Future 기준 점검 3/6
LivaNova (는) 각각 연간 20.7% 및 7.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 11.4% 로 예상됩니다.
핵심 정보
20.7%
이익 성장률
19.57%
EPS 성장률
| Medical Equipment 이익 성장 | 16.1% |
| 매출 성장률 | 7.4% |
| 향후 자기자본이익률 | 11.40% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 07 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • May 05
LIVN: 2026 Outlook And Core Franchises Will Support Constructive Repricing
The updated analyst price target for LivaNova edges slightly lower to about $79.18 from $79.91, even as analysts point to recent Q4 strength, better than expected neuromodulation and cardiopulmonary results, and a solid 2026 outlook as support for their models. Analyst Commentary Recent Street research reflects a generally positive tone on LivaNova, with several firms lifting their price targets following Q4 results and updated 2026 commentary.
내러티브 업데이트 • Apr 20
LIVN: 2026 Core Execution And OSA Expansion Will Test Fair Value View
The analyst price target for LivaNova has been raised by a few dollars per share, with the higher range of $73 to $85 cited in connection with stronger recent results, a firmer 2026 outlook, and expectations for sustained contributions from neuromodulation and cardiopulmonary. Analyst Commentary Recent Street research on LivaNova clusters in a higher target range of about $73 to $85, with most analysts pointing to recent results, solid contributions from neuromodulation and cardiopulmonary, and management's 2026 outlook as key inputs to their updated models.내러티브 업데이트 • Apr 06
LIVN: 2026 Execution In Core Segments Will Test Fair Value View
Analysts have increased the blended price target for LivaNova by several dollars into the low to mid $70s, reflecting Q4 outperformance, constructive 2026 commentary, and updated models that indicate solid contributions from both neuromodulation and cardiopulmonary segments. Analyst Commentary Recent Street commentary around LivaNova clusters around upward revisions to price targets, but the tone is not uniformly bullish.내러티브 업데이트 • Mar 22
LIVN: 2026 Setup And Core Franchises Will Support Constructive Repricing
The updated analyst price target for LivaNova rises from about $73 to roughly $80, reflecting analysts' responses to recent Q4 results, revised models for 2026, and supportive commentary on the company's neuromodulation and cardiopulmonary performance. Analyst Commentary Recent research updates show a cluster of higher price targets for LivaNova, with analysts focusing on Q4 performance, expectations for 2026, and the contribution from neuromodulation and cardiopulmonary.내러티브 업데이트 • Mar 08
LIVN: Fairly Valued As 2026 Outlook Offsets Multiple Compression Risk
The updated analyst price target for LivaNova moves from a fair value estimate of $56 to about $67. Analysts point to recent price target hikes across the Street that reference Q4 outperformance, solid 2026 commentary, and expectations for consistent organic growth as key supports for the revised view.Seeking Alpha • Feb 27
LivaNova: Excellent Performer, But Too Expensive In 2026 (Rating Downgrade)
Summary LivaNova PLC has outperformed the market, but future upside is now more uncertain due to slowing growth and higher valuation. LIVN's 2026 guidance calls for mid-to-high single-digit revenue and EPS growth, with neuromodulation margins notably higher than cardiopulmonary. I upgrade my price target to $68/share but lower my rating to 'HOLD,' citing limited further upside and increased competition risks. Valuation compression is likely as growth moderates, R&D costs rise, and premium multiples become harder to justify without yield. Read the full article on Seeking Alpha
내러티브 업데이트 • Feb 22
LIVN: 2026 Organic Drivers And Medicare Shift Will Support Re Rating
Narrative Update on LivaNova LivaNova’s updated analyst price targets, rising by roughly $8 to $12 per share into the mid to high $60s and low $70s, reflect analysts’ use of higher target multiples in line with comparable MedTech names. They also indicate a view that organic growth will play a larger role in relative valuation from 2026 onward.내러티브 업데이트 • Feb 08
LIVN: Higher 2026 Medtech Multiples And Reimbursement Shift Will Drive Re Rating
Narrative Update on LivaNova LivaNova's analyst price targets have shifted higher into a roughly mid US$60s to US$70 range. Analysts point to adjusted target multiples that align more closely with comparable MedTech names and updated views on organic growth and sector setup into 2026.내러티브 업데이트 • Jan 25
LIVN: Improved Reimbursement And 2026 Reset Will Support Constructive Repricing
Narrative Update The analyst price target on LivaNova has been lifted from about US$69 to roughly US$73 as analysts factor in higher target multiples, in line with recent moves in comparable MedTech names and modestly more constructive views reflected in updated fair value, discount rate, revenue growth, profit margin and forward P/E assumptions. Analyst Commentary Recent research updates on LivaNova cluster around higher price targets and a reset in expectations for 2026, with most of the discussion focused on how the shares should trade relative to other MedTech names as fundamentals and valuation reconnect.내러티브 업데이트 • Jan 09
LIVN: Higher Medtech Multiples And Reimbursement Changes Will Support Re Rating
The analyst fair value estimate for LivaNova has moved from US$80 to US$86, reflecting analysts' use of higher target P/E multiples in line with recent moves in comparable MedTech names and updated views on revenue growth and profit margins. Analyst Commentary Bullish analysts are lifting their targets for LivaNova, pointing to higher target P/E multiples that are more in line with comparable MedTech peers.내러티브 업데이트 • Dec 26
LIVN: Higher Reimbursement Will Still Leave Shares Vulnerable To Multiple Compression
Analysts have modestly raised their price target on LivaNova to $56.00 per share. This reflects slightly stronger long term revenue growth and margin expectations, partially offset by a lower assumed future earnings multiple and a marginally higher discount rate.내러티브 업데이트 • Dec 12
LIVN: Improved Reimbursement And Raised Guidance Will Support Measured 2025 Outlook
Analysts have modestly revised their price target for LivaNova to remain effectively unchanged at approximately 69 dollars per share. This reflects stable assumptions around revenue growth, profitability, and valuation multiples, despite only incremental tweaks to the discount rate and long term earnings expectations.분석 기사 • Dec 07
Improved Revenues Required Before LivaNova PLC (NASDAQ:LIVN) Stock's 26% Jump Looks Justified
LivaNova PLC ( NASDAQ:LIVN ) shareholders would be excited to see that the share price has had a great month, posting a...내러티브 업데이트 • Nov 28
LIVN: Reimbursement Rate Increases And Guidance Raise Will Support 2025 Momentum
Analysts have slightly raised their price target for LivaNova, increasing it from $69.00 to $69.10. This change reflects incremental improvements in profit margin and discount rate assumptions.내러티브 업데이트 • Nov 14
LIVN: Upgraded 2025 Outlook Will Drive Confidence Amid Business Momentum
Narrative Update on LivaNova Analyst Price Target Analysts have raised their price target for LivaNova by $4, now valuing the company at $69.00. This update reflects revised models that take into account management’s updated 2025 outlook and improved revenue growth projections.분석 기사 • Aug 17
Optimistic Investors Push LivaNova PLC (NASDAQ:LIVN) Shares Up 28% But Growth Is Lacking
LivaNova PLC ( NASDAQ:LIVN ) shareholders would be excited to see that the share price has had a great month, posting a...내러티브 업데이트 • Aug 08
Aging Populations And China Expansion Will Drive Device Adoption
Despite consensus revenue growth forecasts increasing to 6.4% and future P/E declining to 26.83x, LivaNova’s analyst price target remained unchanged at $64.70. What's in the News LivaNova raised full-year 2025 revenue growth guidance to 8.0-9.0% (constant currency) and 9.0-10.0% (organic).분석 기사 • Aug 03
LivaNova (NASDAQ:LIVN) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jul 07
LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...분석 기사 • Apr 11
With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For
LivaNova PLC's ( NASDAQ:LIVN ) price-to-earnings (or "P/E") ratio of 29.3x might make it look like a strong sell right...분석 기사 • Mar 21
Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now?
LivaNova PLC ( NASDAQ:LIVN ), is not the largest company out there, but it received a lot of attention from a...
새로운 내러티브 • Mar 11
Investment In Obstructive Sleep Apnea And DTD Therapies Will Strengthen Future Market Position
Strategic focus on obstructive sleep apnea and cardiopulmonary advancements is key for revenue growth and market expansion.분석 기사 • Feb 28
LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a mediocre week for LivaNova PLC ( NASDAQ:LIVN ) shareholders, with the stock dropping 15% to US$40.93 in the...분석 기사 • Feb 25
We Like These Underlying Return On Capital Trends At LivaNova (NASDAQ:LIVN)
What are the early trends we should look for to identify a stock that could multiply in value over the long term...분석 기사 • Dec 28
LivaNova PLC's (NASDAQ:LIVN) Price Is Right But Growth Is Lacking
You may think that with a price-to-sales (or "P/S") ratio of 2x LivaNova PLC ( NASDAQ:LIVN ) is a stock worth checking...분석 기사 • Nov 12
We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Even though LivaNova PLC ( NASDAQ:LIVN ) posted strong earnings, investors appeared to be underwhelmed. We did some...분석 기사 • Nov 03
LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
A week ago, LivaNova PLC ( NASDAQ:LIVN ) came out with a strong set of third-quarter numbers that could potentially...분석 기사 • Oct 31
LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Seeking Alpha • Oct 18
LivaNova: Economics Should Start Making Sustained Improvements
Summary LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth. Despite potential liabilities from an Italian lawsuit, valuation looks compelling based on implied value of the DTD option, where they will decide on commercialization next year. Even outside the DTD growth opportunity, recurring economics and medical device industry margins suggest sustained improvements in economics coming. Read the full article on Seeking Alpha분석 기사 • Oct 02
Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?
Key Insights The projected fair value for LivaNova is US$76.07 based on 2 Stage Free Cash Flow to Equity Current share...분석 기사 • Aug 21
LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares
LivaNova PLC's ( NASDAQ:LIVN ) price-to-sales (or "P/S") ratio of 2.1x might make it look like a buy right now compared...분석 기사 • Jul 30
LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...분석 기사 • Jul 04
At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?
LivaNova PLC ( NASDAQ:LIVN ), is not the largest company out there, but it saw significant share price movement during...분석 기사 • Jun 13
Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?
Key Insights LivaNova's estimated fair value is US$76.63 based on 2 Stage Free Cash Flow to Equity Current share price...Seeking Alpha • May 12
LivaNova: Focus Is Paying Off
Summary LivaNova has streamlined operations and increased income by shutting down ANTHEM trials and releasing new, premium products. Operating margins have improved from 10% to 18% due to savings in R&D and the mix effects from Essenz. LIVN's epilepsy products are scaling, with new implants driving growth and a strong recurring revenue base. Capacity expansions are coming for oxygenators which will increase cardiopulmonary segment volumes starting next quarter. Remaining trials are promising yet are being given an implied negative options value, a testament to the existing businesses and also to the value case. Read the full article on Seeking Alpha분석 기사 • Apr 08
These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong
When researching a stock for investment, what can tell us that the company is in decline? Businesses in decline often...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 1,730 | 208 | 236 | 304 | 7 |
| 12/31/2027 | 1,614 | 179 | 220 | 294 | 10 |
| 12/31/2026 | 1,508 | 146 | 161 | 280 | 10 |
| 3/31/2026 | 1,433 | 107 | 161 | 246 | N/A |
| 12/31/2025 | 1,388 | -242 | 173 | 254 | N/A |
| 9/30/2025 | 1,349 | -217 | 191 | 251 | N/A |
| 6/30/2025 | 1,309 | -211 | 162 | 217 | N/A |
| 3/31/2025 | 1,275 | -222 | 146 | 197 | N/A |
| 12/31/2024 | 1,253 | 63 | 136 | 183 | N/A |
| 9/30/2024 | 1,242 | 24 | 109 | 158 | N/A |
| 6/30/2024 | 1,210 | -17 | 85 | 125 | N/A |
| 3/31/2024 | 1,185 | -32 | 30 | 64 | N/A |
| 12/31/2023 | 1,154 | 18 | 40 | 75 | N/A |
| 9/30/2023 | 1,118 | 3 | 8 | 40 | N/A |
| 6/30/2023 | 1,085 | -97 | 29 | 57 | N/A |
| 3/31/2023 | 1,045 | -82 | 36 | 65 | N/A |
| 12/31/2022 | 1,022 | -86 | 43 | 70 | N/A |
| 9/30/2022 | 1,017 | -93 | 60 | 85 | N/A |
| 6/30/2022 | 1,018 | -29 | 51 | 73 | N/A |
| 3/31/2022 | 1,028 | -102 | 86 | 109 | N/A |
| 12/31/2021 | 1,035 | -136 | 77 | 103 | N/A |
| 9/30/2021 | 1,035 | -414 | 82 | 106 | N/A |
| 6/30/2021 | 1,022 | -385 | 59 | 91 | N/A |
| 3/31/2021 | 939 | -417 | 11 | 46 | N/A |
| 12/31/2020 | 934 | -347 | -114 | -79 | N/A |
| 9/30/2020 | 952 | -208 | -150 | -114 | N/A |
| 6/30/2020 | 981 | -161 | -234 | -199 | N/A |
| 3/31/2020 | 1,076 | -102 | -230 | -199 | N/A |
| 12/31/2019 | 1,084 | -158 | N/A | -91 | N/A |
| 9/30/2019 | 1,094 | -222 | N/A | -73 | N/A |
| 6/30/2019 | 1,097 | -260 | N/A | 55 | N/A |
| 3/31/2019 | 1,107 | -211 | N/A | 102 | N/A |
| 12/31/2018 | 1,107 | -178 | N/A | 120 | N/A |
| 9/30/2018 | 1,088 | 0 | N/A | 117 | N/A |
| 6/30/2018 | 1,068 | 33 | N/A | 108 | N/A |
| 3/31/2018 | 1,036 | 59 | N/A | 79 | N/A |
| 12/31/2017 | 1,012 | 54 | N/A | 91 | N/A |
| 9/30/2017 | 795 | 121 | N/A | 114 | N/A |
| 6/30/2017 | 840 | 92 | N/A | 109 | N/A |
| 3/31/2017 | 905 | 55 | N/A | 114 | N/A |
| 12/31/2016 | 965 | 2 | N/A | 90 | N/A |
| 12/31/2015 | 545 | -22 | N/A | -14 | N/A |
| 10/18/2015 | 295 | 14 | N/A | 87 | N/A |
| 7/24/2015 | 301 | 57 | N/A | 80 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: LIVN 의 연간 예상 수익 증가율(20.7%)이 saving rate(3.5%)보다 높습니다.
수익 vs 시장: LIVN 의 연간 수익(20.7%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 수익: LIVN 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.
수익 대 시장: LIVN 의 수익(연간 7.4%)이 US 시장(연간 11.8%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: LIVN 의 수익(연간 7.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: LIVN의 자본 수익률은 3년 후 11.4%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 11:18 |
| 종가 | 2026/05/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
LivaNova PLC는 26명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Rescott | Baird |
| Matthew Miksic | Barclays |
| Scott Bardo | Berenberg |